Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The study builds on a successful collaboration and will compare T cell and antibody responses to uncover the role of ‘background’ immunity to virus strains already in circulation, including infections with similar coronaviruses.

Busy street of peoples in Sri Lanka (Colombo - photo on left) and UK (London - photo on right).

The study is led by Professor Graham Ogg, who currently heads the MRC Human Immunology Unit at the MRC Weatherall Institute of Molecular Medicine, and Professor Neelika Malavige at the University of Sri Jayewardenepura. Professor Malavige is also a visiting researcher at Oxford University.

“We have worked together for 12 years to understand the response to dengue infections, and we now want to bring the expertise and knowledge we’ve acquired to understand the immune responses in individuals with COVID-19,” said Professor Ogg.

Current research indicates that immune responses to the novel SARS-CoV2 may be a key that distinguishes only a mild illness after infection from a more serious condition, but the workings of these immune responses are still poorly understood.

By comparing immune markers in blood samples from the UK versus Sri Lanka, the researchers hope to understand how existing immunity to different viruses (including other coronaviruses) might influence the immune response to a COVID-19 infection.

“This kind of existing immunity may play a protective role, or it may worsen disease severity – we just don’t know yet” said Professor Ogg. “By comparing immune responses from two different populations with exposure to different kinds of pathogens, we hope to get a clearer answer to this question.”

So the researchers will be analysing blood samples from the general population, as well as current and recovered COVID-19 patients in both the UK and Sri Lanka, to see how different kinds of existing immunity affect disease. They are particularly interested in T cells, (a kind of white blood cell that is crucial for adapting the body’s immune response to specific pathogens), as well as antibodies (a blood protein manufactured by the body to attack specific pathogens).

“By comparing immune responses from two different populations with exposure to different kinds of pathogens, we hope to get a clearer answer about how background immunity influences COVID-19 disease”, said Professor Graham Ogg.

Similar stories

Mechanism behind repair of cancer-inducing mutations discovered

New Nature paper uncovers the precise mechanism behind how the BRCA1 protein detects and engages with DNA breaks in the genome, helping to prevent the development of breast and ovarian cancers.

DNA breakthrough could help identify why some people are more affected by Covid-19

Scientists from the MRC Weatherall Institute of Molecular Medicine have developed a method that allows them to see, with far greater accuracy, how DNA forms large scale structures within a cell nucleus.

New clinical trial for patients affected by blood cancer

Radcliffe Department of Medicine's Professor Adam Mead is leading PROMise, a new clinical trial offering a novel treatment option for patients with a type of blood cancer called myelofibrosis.

Immune cells imperfect at distinguishing friend from foe

When it comes to distinguishing a healthy cell from an infected one that needs to be destroyed, the immune system’s killer T cells sometimes make mistakes. This discovery, described today in the journal eLife, upends a long-held belief among scientists that T cells were nearly perfect at discriminating friend from foe. The results may point to new ways to treat autoimmune diseases that cause the immune system to attack the body, or lead to improvements in cutting-edge cancer treatments.

Professor Graham Ogg elected Academy of Medical Sciences Fellow

Fellows are selected for their exceptional contributions to the advancement of medical science through innovative research discoveries and translating scientific developments into benefits for patients and the wider society.